On September 26, world leaders will convene in New York for the first-ever United Nations (UN) High-Level Meeting on Ending Tuberculosis (TB). This event could not be more critical – or more timely – because even though TB kills more than one million people per year, it has not received enough attention from global policymakers.
As the world prepares to make desperately needed new commitments to end TB, the discussion on how best to tackle this challenge has at times become mired in unnecessary controversy. Instead of working to find practical solutions, some groups have used this meeting to advance old myths that have little to do with today’s reality or the unique challenges of treating TB.
Myth: TB is no longer a major global health challenge.
Fact: TB continues to be a significant health challenge, and is one of the top ten causes of death and the leading cause of infectious disease-related deaths worldwide. Multiple-drug resistant TB (MDR-TB) presents a particular threat and has been deemed a “public health crisis” by the World Health Organization. Fortunately, there has been significant progress in fighting the disease to build upon: an estimated 53 million lives were saved through TB diagnosis and treatment between 2000 and 2016.
Myth: Patients aren’t getting the treatment they need because TB medicines are too expensive.
Fact: Most first-line medicines used to treat TB are generics available at low prices. A full six-month course of treatment for a patient with TB costs less than $20. New patented medicines developed for MDR-TB are widely available with deep discounts and robust access programs made possible through donations, partnerships, differential pricing and voluntary licensing agreements. In developing countries, particularly those most impacted by TB, non-profit organizations like Global Drug Facility and Global Fund make TB drugs available at little to no cost through public-sector procurement funds. Unfortunately, despite these comprehensive and expansive efforts, many countries are not taking full advantage of these funds and at least one-third of high-burden countries have left global donor funding for TB on the table.
Myth: The biggest obstacle to fighting TB worldwide is the cost of medicines.
Fact: The treatment of TB is remarkably complex. It requires advanced diagnostics, trained health care professionals, well-run clinics and effective systems to monitor months-long treatments. Compared to these expenses, the list price of the medicines is not a significant barrier to patient access. Most TB-afflicted countries lack strong and appropriately funded health care systems, which are big obstacles. To meaningfully address TB, there must be a focus on the real barriers to TB care, such as the limited availability of diagnostics, a lack of centralized models of care and inefficient regulatory approval systems, all of which stand in the way of effectively diagnosing and treating patients with TB. Further, innovative TB treatments may in fact help save costs. For example, research has shown that development of a TB medicine that cuts the duration of treatment from 6 months to 4 months would significantly reduce costs and allow patients to more quickly return to productive activities.
Myth: Weakening IP protections will help fight TB.
Fact: Undermining IP protections will not meaningfully improve access to TB medicines, but it will harm an already fragile innovation environment. While critics often point to IP as a barrier to access to medicines, there is little evidence that this is the case. In fact, one study analyzed 21 factors that could potentially limit access to medicines in low- and middle-income countries and found no correlation between IP protections and a lack of access to treatments and cures. For TB in particular—where, according to the WHO, investment into new drugs is at its lowest level since 2008—incentivizing research and development is especially important. Effective IP protections can encourage inventors to make the risky investments necessary to discover new TB medicines and bring them to patients.
Myth: The United States government supports IP protections so corporations can reap profits.
Fact: The U.S., as the home to some of the world’s most innovative companies, has long recognized the value of IP in incentivizing research and development. Successive Democratic and Republican administrations have championed the global system of IP protection to foster innovation and save lives around the world. In recent years, the Obama administration opposed anti-IP language in other UN declarations and committed itself “to advancing access to existing and new medicines, including by supporting innovation through robust intellectual property protections.” The current U.S. administration has continued to oppose language at the UN that would discourage urgently-needed private sector R&D into new medical treatments. Research shows that IP is not a significant barrier to access and helps promote improvements in access to medicines, including those used to treat TB.
Download the fact sheet on global TB innovation here.
Megan Van Etten
Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Megan Van Etten
Bayh-Dole: The fuel for America’s innovation engine
Setting the record straight: 3 facts about drug patents
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
MFN could disrupt the affordable medicines patients depend on
Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings
Argentina sets course to enable innovation by rejecting failed patent rules
16 years later: How BPCIA continues to expand competition and lower costs
Key context is often missing from the debate over the Patent Trial and Appeal Board
MFN undermines U.S. biopharmaceutical innovation
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
How post-approval innovation keeps delivering for patients
PhRMA calls on USTR to ensure foreign nations pay their fair share
Three things to know about Bayh-Dole: Innovation that pays off for taxpayers
Delivering breakthroughs and lower costs for patients
PBMs, not patents, are blocking access to lower-cost medicines
New report: How intellectual property drives U.S. innovation and biopharma's impact
New report: Post-approval innovation delivers substantial patient benefits
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
USTR 2025 Special 301 Report corrects course
From sound to science: How IP powers innovation in music and hearing
How the IRA is impacting the generic drug market
3 myths critics get wrong about intellectual property
ICYMI: PhRMA submits comments to White House on artificial intelligence
PhRMA submission calls for USTR to correct course on trade policy, enforcement
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
New research: American biopharmaceutical investment in R&D drives transformational innovation
Biden Administration report debunks myths around patent “evergreening” and “thickets”
What to know about the latest effort to break patents using a legally dubious avenue
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
PhRMA launches education campaign on the benefits of America's IP system
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Experts discuss the value of IP at Senate Judiciary Committee hearing
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
World IP Day 2024: Supporting an innovative and sustainable future
International meetings hold big implications for Americans and our innovation ecosystem
Proposed march-in framework would chill American innovation
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
The White House continues to attack American innovation
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
Misuse of march-in could stifle innovation
WHO Pandemic Agreement offers opportunities and risks for American innovators
Word of the Month: The Bayh-Dole Act
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
It’s PBMs, not patents, blocking competition
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
WTAS on reasonable pricing and public-private partnerships
Key considerations as Congress works towards PAHPA reauthorization
Reject efforts to undermine America’s R&D ecosystem
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
Setting the record straight on the Bayh-Dole Act and March-in
World IP Day 2023: Celebrating women leaders in innovation
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
New global analysis shows patient access challenges around the world
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
U.S. biopharmaceutical exports support jobs, innovation
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
U.S. must address IP and market access barriers abroad to protect American innovation
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
Six ways I-MAK is lying about biopharma patents
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
PhRMA submission to USTR calls for urgent defense of American innovation abroad
The law driving technology transfer and fostering innovation
Don’t take anti-innovation, activist funded academics at their word
New report ignores benefits of patent system to innovation and patients
Partnerships are driving global COVID-19 treatment access
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
Patent policy changes proposed by USPTO and FDA would leave patients behind
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework
Research and development continues long after a medicine is initially approved
Protecting U.S. innovation abroad to support economic and pandemic recovery
Legislation threatens patent protections and future innovation
Global COVID-19 vaccination matters now and for the future
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
Patients and innovators lose if the government pursues ‘march-in’
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Increasing global access to vaccines by optimizing production
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
New report demonstrates development of new medicines relies on private sector expertise and investment
American leadership on innovation policy is essential to global health progress
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
Intellectual property is the key to vaccine development, manufacturing and technology sharing
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Preserving U.S. innovation worldwide is more important than ever
New video: See how strong IP protections lead to stronger treatments for patients
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
IP Explained: Intellectual property system working to combat COVID-19
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
The continued imperative to protect U.S. innovation worldwide
IP Explained: Four key takeaways from new Bayh-Dole white paper
Trump administration must defend and protect U.S. innovation
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
IP Explained: Four things to know about the Bayh-Dole Act
IP Explained: Understanding biopharmaceutical innovation
IP Explained: Why IP protections are important for biologic medicines
IP Explained: What is Section 101 and why reforms are needed
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
World Trade Month: How we can expand world-class pro-innovation standards
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
IP Explained: What they are saying on the importance of strong intellectual property protections
IP Explained: Why patents are so critical to biopharmaceutical innovation
New report: Using march-in authority would jeopardize U.S. innovation
Special 301 submission calls for a level playing field for American innovators
Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
What is inter partes review and why does it matter?
Supporting opportunities for enhanced competition in the marketplace
Biopharma leads sustained economic growth driven by IP-intensive industries
Opportunities to build upon enhanced competition for medicines in the marketplace
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
Illegal trade barriers discriminate against U.S. innovators
Trading fair means upholding the law: A focus on patents
Enforcing unmet trade obligations protects U.S. innovation
NAFTA tribunal fails to rule on Canada’s patent utility doctrine
PhRMA urges USTR to protect American innovators abroad
Five myths about global efforts to combat tuberculosis
Intellectual Property
Five myths about global efforts to combat tuberculosis
Five myths about global efforts to combat tuberculosis